EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single‐Center Study

Wen-Chi Wu iD, I-Wei Ho, San-Chi Chen iD, Paul Chih-Hsueh Chen, Po-Kuei Wu, Chao-Ming Chen, Hung-Ta Wu, Chung-Jung Lin, Ta-Chung Chao, Chueh-Chuan Yen

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.04.2026. Verfasst von Wen-Chi Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taipei Veterans General Hospital, "National Science and Technology Council, Taiwan" funderDoi="10.13039/100020595".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced sarcomas have limited treatment options. Gemcitabine and docetaxel (GD) regimen showed efficacy in soft tissue sarcomas (STSs) in phase II studies but failed in first‐line phase III trial. Adding cisplatin to GD showed efficacy in other types of cancer. mTOR pathway has been shown to play a role in resistance to these drugs. Inflammatory biomarkers have been identified as potential prognostic indicators in various malignancies, but their role in patients with advanced sarcomas is not clear.

Methods

We retrospectively enrolled 77 patients with advanced or metastatic sarcomas (STSs, n = 71; bone sarcomas, n = 6) receiving a novel combination with gemcitabine‐gemcitabine/docetaxel/cisplatin plus everolimus (G‐GDC + E). Primary endpoints included overall survival (OS) and progression‐free survival (PFS). Inflammatory biomarkers were calculated, and their prognostic influence was evaluated.

Results

The median OS and PFS were 16.8 months (95% CI, 13.6–23.9) and 5.4 months (95% CI, 4.3–8.3), respectively. Undifferentiated pleomorphic sarcoma/myxofibrosarcoma (UPS/MFS) demonstrated superior PFS compared to round cell sarcoma/translocation‐related sarcoma (7.8 vs. 3.6 months, p = 0.009) and bone sarcoma (7.8 vs. 2.3 months, p < 0.001). Eastern Cooperative Oncology Group Performance Status ≥ 2, unfavorable histology (round cell sarcoma/translocation‐related sarcoma and bone sarcoma), lower albumin level, and lymphocyte‐to‐monocyte ratio < 2.7 were independent predictors of OS. Grade 3–4 toxicities included neutropenia (68.8%), thrombocytopenia (59.7%), anemia (49.4%), diarrhea (18.2%), and skin toxicities (28.6%).

Conclusions

G‐GDC + E demonstrates histology‐specific efficacy in advanced/metastatic sarcomas, with substantial hematologic toxicity (Grade 3–4 thrombocytopenia 59.7%, neutropenia 68.8%) and notable non‐hematologic events (Grade 3–4 diarrhea 18.2%, skin reactions 28.6%), all controllable with close monitoring, dose modifications and supportive care. Inflammatory biomarkers provide independent prognostic values.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaAntineoplastic Combined Chemotherapy ProtocolsHumansDocetaxelCisplatinFemaleDeoxycytidineGemcitabineRetrospective StudiesEverolimusMaleMiddle AgedAgedAdultPrognosisTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

cisplatindocetaxeleverolimusgemcitabinesarcomasystemic inflammation biomarkers

Substanzen

DocetaxelCisplatinDeoxycytidineGemcitabineEverolimus

Autor:innen und Institutionen

  • Division of Medical Oncology, Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Departments of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Joint Reconstruction, Department of Orthopedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.

ORCID-Profile: Wen-Chi Wu, San-Chi Chen

Förderung

  • Taipei Veterans General Hospital
  • "National Science and Technology Council, Taiwan" funderDoi="10.13039/100020595"

Zitieren

APA

Wu, W. C., Ho, I. W., Chen, S. C., Chen, P. C., Wu, P. K., Chen, C. M., Wu, H. T., Lin, C. J., Chao, T. C., & Yen, C. C. (2026). Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single‐Center Study. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71852

Vancouver

Wu WC, Ho IW, Chen SC, Chen PC, Wu PK, Chen CM, et al. Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single‐Center Study. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71852

BibTeX
@article{Wu2026,
  author = {Wu, Wen-Chi and Ho, I-Wei and Chen, San-Chi and Chen, Paul Chih-Hsueh and Wu, Po-Kuei and Chen, Chao-Ming and Wu, Hung-Ta and Lin, Chung-Jung and Chao, Ta-Chung and Yen, Chueh-Chuan},
  title = {Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single‐Center Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71852}
}
Kostenlos starten →